LONG TERM DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PATIENTS WITH A NON-MEDICAL SWITCH FROM ETANERCEPT REFERENCE DRUG

被引：0
|
作者：
Haugeberg, Glenn [1 ]
Fevang, Bjorg Tilde Svanes [2 ]
Bakland, Gunnstein [3 ]
Rodevand, Erik [4 ]
Diamantopoulos, Andreas [5 ]
机构：
[1] Sorlandet Hosp Kristiansand, Rheumatol, Kristiansand, Norway
[2] Haukeland Hosp, Rheumatol, Bergen, Norway
[3] Univ Hosp North Norway HF, Rheumatol, Tromso, Norway
[4] St Olavs Hosp HF, Rheumatol, Trondheim, Norway
[5] Martina Hansens Hosp, Rheumatol, Baerum, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.7387
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0094
引用
收藏
页码：710 / 711
页数：2
相关论文
共 50 条
  • [21] Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate
    Visman, I. M.
    l'Ami, M. J.
    Wolbink, Gertjan
    Nurmohamed, Mike T.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [22] ANALYSIS OF RHEUMATOID ARTHRITIS PATIENTS WHO FAILED THE SWITCH FROM ORIGINATOR ETANERCEPT TO BIOSIMILAR ETANERCEPT IN CROYDON
    Patel, Dimil
    Ahmed, Tazeen J.
    Levy, Sarah
    Rajak, Rizwan
    Sathananthan, Rosh
    Horwood, Natalie
    RHEUMATOLOGY, 2018, 57
  • [23] Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study
    Bonifati, C.
    De Felice, C.
    Lora, V
    Morrone, A.
    Graceffa, D.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (07) : 687 - 691
  • [24] LONG-TERM DRUG SURVIVAL OF ETANERCEPT VS OTHER TNF INHIBITOR THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Emery, P.
    Vlahos, B.
    Szczypa, P.
    Thakur, M.
    Jones, H. E.
    Woolcott, J.
    Estrella, P. V. Santos
    Gibofsky, A.
    Rolland, C.
    Citera, G.
    Marshall, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1391 - 1392
  • [25] MAINTENANCE AND IMPROVEMENT IN CLINICAL EFFICACY BETWEEN WEEK 12 AND 24 IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SB4 OR REFERENCE ETANERCEPT
    Emery, P.
    Vencovsky, J.
    Keystone, E.
    Ghil, J.
    Cheong, S. Y.
    Hong, E. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 834 - 834
  • [26] DRUG SURVIVAL ON CERTOLIZUMAB AND PREDICTORS THEREOF IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL-SPONDYLOARTHRITIS FROM THE APULIAN BIOPURE REGISTRY
    Semeraro, A.
    Carlino, G.
    Bucci, R.
    D'Onofrio, F.
    Falappone, P. C.
    Lopriore, S.
    Marsico, A.
    Maruotti, N.
    Mazzotta, D.
    Muratore, M.
    Quarta, L.
    Santo, L.
    Zuccaro, C.
    Iannone, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1374 - 1374
  • [27] Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort
    Codreanu, Catalin
    Popescu, Claudiu C.
    Mogosan, Corina
    Enache, Luminita
    Daia, Sanziana
    Ionescu, Ruxandra
    Opris-Belinski, Daniela
    BIOLOGICALS, 2019, 62 : 27 - 32
  • [28] Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching
    Cantini, Fabrizio
    Benucci, Maurizio
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (02)
  • [29] CERTOLIZUMAB PEGOL PERSISTENCE AND ADHERENCE BY DRUG FORMULATION, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, OR RHEUMATOID ARTHRITIS
    Beaty, S.
    Zichlin, M. L.
    Hopson, S.
    Devine, F.
    Pi, S.
    Moore, J.
    Swallow, E.
    VALUE IN HEALTH, 2022, 25 (07) : S561 - S561
  • [30] SATISFACTION WITH THE BDMARD ETANERCEPT BIOSIMILAR (SB4) PRE-FILLED PEN AMONG RHEUMATOID ARTHRITIS AND SPONDYLOARTHROPATHY PATIENTS; A GERMAN OBSERVATIONAL STUDY
    Mueller-Ladner, U.
    Zinke, S.
    Aries, P. M.
    Maucksch, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1864 - 1865
12345